Etoposide plus cisplatin shows higher treatment completion rate of 89.0% vs. 74.1% in HGNEC
Trial Shows Etoposide and Cisplatin for Neuroendocrine Lung Carcinoma
This post hoc analysis of a Phase III trial evaluated 217 patients with high-grade neuroendocrine carcinoma of the lung who underwent comple…
A trial of 217 patients with lung cancer found that higher doses of certain chemotherapy drugs did not lead to better outcomes.
Irinotecan plus cisplatin shows no RFS benefit over etoposide plus cisplatin in resected lung HGNEC
Five-year follow-up shows irinotecan plus cisplatin matches etoposide plus cisplatin for lung cancer survival
This randomized, open-label, phase III study compared irinotecan plus cisplatin to etoposide plus cisplatin in 221 patients with resected hi…
A five-year look at lung cancer patients found that irinotecan plus cisplatin worked just as well as etoposide plus cisplatin for keeping th…